- PR Newswire•21 hours ago
OSAKA, Japan, Dec. 9, 2016 /PRNewswire/ -- Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") announced that an analysis based on pre-specified and post-hoc exploratory outcomes of GEMINI II and GEMINI III data evaluating Entyvio (vedolizumab) therapy in patients with moderately to severely active Crohn's disease (CD) was published in Inflammatory Bowel Diseases. The data demonstrated higher rates of response in patients receiving vedolizumab as a first-line biologic after conventional therapy failure versus patients who had previously experienced tumor necrosis factor-alpha (TNF-alpha) antagonist therapy failure.
- PR Newswire•2 days agoTakeda Presents 17 Abstracts at the 2016 Advances in Inflammatory Bowel Diseases (AIBD) Annual Conference
DEERFIELD, Ill., Dec. 8, 2016 /PRNewswire/ -- Takeda Pharmaceuticals, U.S.A., Inc. ("Takeda"), today announced that data highlighting the efficacy and safety of vedolizumab for the treatment ...
- Insider Monkey•9 days agoValeant Pharmaceuticals Intl Inc (VRX) To Retain Salix Pharmaceuticals, Ltd. (SLXP) After Negotiations With Takeda Pharmaceutical Co Ltd (ADR) (TKPYY) Collapse
Buyout talks between Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Takeda Pharmaceutical Co Ltd (ADR) (OTCMKTS:TKPYY) that would have resulted in the sale of Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), which Valeant owns, have broken down. The negotiations could be revived, but Valeant doesn’t seem keen on resuming talks to sell its Salix business as it has already […]
TKPYY : Summary for TAKEDA PHARMACEUTI SPON ADR EA - Yahoo Finance
Takeda Pharmaceutical Company Limited (TKPYY)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||20.30 - 20.53|
|52 Week Range||20.00 - 25.50|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||24.14|
|Dividend & Yield||0.78 (3.85%)|
|1y Target Est||N/A|